JP2021501220A5 - - Google Patents

Download PDF

Info

Publication number
JP2021501220A5
JP2021501220A5 JP2020544333A JP2020544333A JP2021501220A5 JP 2021501220 A5 JP2021501220 A5 JP 2021501220A5 JP 2020544333 A JP2020544333 A JP 2020544333A JP 2020544333 A JP2020544333 A JP 2020544333A JP 2021501220 A5 JP2021501220 A5 JP 2021501220A5
Authority
JP
Japan
Prior art keywords
methoxy
cyclopropyl
isoxazole
octane
bicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020544333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501220A (ja
JP7212693B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/058315 external-priority patent/WO2019089667A1/en
Publication of JP2021501220A publication Critical patent/JP2021501220A/ja
Publication of JP2021501220A5 publication Critical patent/JP2021501220A5/ja
Application granted granted Critical
Publication of JP7212693B2 publication Critical patent/JP7212693B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020544333A 2017-11-01 2018-10-31 ファルネソイドx受容体モジュレーターとしての架橋二環化合物 Active JP7212693B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762580075P 2017-11-01 2017-11-01
US62/580,075 2017-11-01
PCT/US2018/058315 WO2019089667A1 (en) 2017-11-01 2018-10-31 Bridged bicyclic compounds as farnesoid x receptor modulators

Publications (3)

Publication Number Publication Date
JP2021501220A JP2021501220A (ja) 2021-01-14
JP2021501220A5 true JP2021501220A5 (enExample) 2021-11-11
JP7212693B2 JP7212693B2 (ja) 2023-01-25

Family

ID=64332182

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544333A Active JP7212693B2 (ja) 2017-11-01 2018-10-31 ファルネソイドx受容体モジュレーターとしての架橋二環化合物

Country Status (19)

Country Link
US (1) US10730863B2 (enExample)
EP (1) EP3704113B1 (enExample)
JP (1) JP7212693B2 (enExample)
KR (1) KR102732835B1 (enExample)
CN (1) CN111295382B (enExample)
AR (1) AR113820A1 (enExample)
AU (1) AU2018360577A1 (enExample)
BR (1) BR112020008457A2 (enExample)
CA (1) CA3079833A1 (enExample)
CL (1) CL2020001138A1 (enExample)
CO (1) CO2020005459A2 (enExample)
EA (1) EA202091063A1 (enExample)
ES (1) ES2964964T3 (enExample)
IL (1) IL274321A (enExample)
MX (1) MX2020004405A (enExample)
PE (1) PE20201170A1 (enExample)
SG (1) SG11202003827YA (enExample)
TW (1) TW201922722A (enExample)
WO (1) WO2019089667A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2020081257A1 (en) 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
EP3924337A1 (en) 2019-02-15 2021-12-22 Bristol-Myers Squibb Company Substituted bicyclic compounds as farnesoid x receptor modulators
EP3924333A1 (en) 2019-02-15 2021-12-22 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid x receptor modulators
JP7449300B2 (ja) 2019-02-15 2024-03-13 ブリストル-マイヤーズ スクイブ カンパニー ファルネソイドx受容体モジュレータとして有用な置換アミド化合物
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
TW202108559A (zh) 2019-05-31 2021-03-01 美商醫肯納腫瘤學公司 Tead抑制劑及其用途
CN110804025B (zh) * 2019-11-29 2022-02-08 扬州工业职业技术学院 一种卤代苯异噁唑衍生物及其制备方法与应用
CN110922368B (zh) * 2019-11-29 2022-08-16 扬州工业职业技术学院 一种氯代苯异噁唑氨基苯甲酸衍生物及其制备方法与应用
US20230060715A1 (en) 2020-01-15 2023-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ1-アンチトリプシンのモジュレーター
JP7791102B2 (ja) * 2020-04-03 2025-12-23 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ1-アンチトリプシンのモジュレーター
WO2022120353A1 (en) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
US20240100125A1 (en) 2021-01-14 2024-03-28 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてfxrアゴニストを使用するtlr3アゴニストの効果の強い増強
US20240287051A1 (en) * 2021-06-11 2024-08-29 Otsuka Pharmaceutical Co., Ltd. Process for preparing an erk inhibitor
CN115504972B (zh) * 2021-06-22 2024-11-12 广东药科大学 异恶唑类衍生物、其制备方法及其作为药物的用途
CN119894870A (zh) 2022-09-19 2025-04-25 巴斯夫欧洲公司 唑杀有害生物化合物
CN117105779A (zh) * 2023-07-18 2023-11-24 河南师范大学 一种5-溴-2-甲酰基苯甲酸甲酯的制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013101A1 (fr) 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
AU4999897A (en) 1996-10-25 1998-05-15 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
EP1071655A1 (en) 1998-04-17 2001-01-31 Kenneth Curry Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation
EP2305684A1 (en) 1999-11-12 2011-04-06 Biogen Idec MA Inc. Poycyloalkylpurines as adenosine receptor antagonists
AU2001255408A1 (en) 2000-04-14 2001-10-30 Corvas International, Inc. Tetrahydro-azepinone derivatives as thrombin inhibitors
ATE360614T1 (de) 2001-06-21 2007-05-15 Cesare Casagrande Verbindung für die behandlung von atherosclerotischen und thrombotischen erkrankungen
AU2003264018A1 (en) 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
WO2006007503A1 (en) 2004-07-01 2006-01-19 Wyeth Tetracyclic compounds as estrogen ligands
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
CA2603402C (en) 2005-04-08 2017-10-31 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
ES2374165T3 (es) 2005-12-19 2012-02-14 Glaxosmithkline Llc Agonistas del receptor x farnesoide.
AU2007292993B2 (en) 2006-09-07 2013-01-24 Idorsia Pharmaceuticals Ltd Pyridin-4-yl derivatives as immunomodulating agents
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
US20100035918A1 (en) 2007-01-30 2010-02-11 Biogen Idec Ma Inc Imidazolone Compounds and Methods of Making and Using the Same
CA2690406A1 (en) 2007-07-02 2009-01-08 Glaxosmithkline Llc Farnesoid x receptor agonists
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
KR20100075643A (ko) 2007-10-22 2010-07-02 쉐링 코포레이션 비사이클릭 헤테로사이클 유도체 및 gpr119의 활성의 조절인자로서의 이의 용도
CA2741839A1 (en) 2008-11-21 2010-05-27 Pfizer Inc. 1-oxa-8-azaspiro [4,5] decane-8-carboxamide compounds as faah inhibitors
EP2403849B1 (en) 2009-03-03 2014-07-16 Merck Serono S.A. Oxazole pyridine derivatives useful as S1P1 receptor agonists
EP2427455B1 (en) 2009-05-05 2020-01-15 F.Hoffmann-La Roche Ag Isoxazole-pyrazole derivatives
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
TW201300380A (zh) 2010-10-19 2013-01-01 Comentis Inc 抑制β-分泌酶活性之噁二唑化合物及其使用方法
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
AU2012245387C1 (en) 2011-04-22 2016-05-05 Signal Pharmaceuticals, Llc Substituted Diaminocarboxamide and Diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
HRP20161774T1 (hr) 2012-06-13 2017-02-24 F. Hoffmann - La Roche Ag Novi diazaspirocikloalkan i azaspirocikloalkan
JP6099753B2 (ja) 2012-10-03 2017-03-22 アドビナス セラピューティクス リミテッド スピロ環化合物、その組成物及びその医薬応用
WO2014071247A1 (en) 2012-11-02 2014-05-08 Dana-Farber Cancer Institute, Inc. Pyrrol-1 -yl benzoic acid derivates useful as myc inhibitors
EP2774919A1 (en) 2013-03-06 2014-09-10 Pharmeste S.R.L. In Liquidazione Novel sulfonamide TRPA1 receptor antagonists
MX366820B (es) 2013-03-14 2019-07-25 Bristol Myers Squibb Co Moduladores de gpr120 del acido biciclo[2.2.2].
UY35834A (es) 2013-11-14 2015-05-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
WO2015172747A1 (en) 2014-05-16 2015-11-19 Zhaoyin Wang Spirocyclic molecules as mth1 inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
BR112017011972A2 (pt) 2014-12-18 2017-12-26 Novartis Ag derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
CN106146483A (zh) * 2015-04-23 2016-11-23 上海迪诺医药科技有限公司 杂环类法尼酯衍生物x受体调节剂
CN106946867B (zh) * 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
CN107021958A (zh) 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
WO2017133521A1 (zh) 2016-02-01 2017-08-10 山东轩竹医药科技有限公司 Fxr受体激动剂
DK3419625T3 (da) 2016-02-22 2021-07-12 Novartis Ag Fremgangsmåder til anvendelse af fxr-agonister
JP6941109B2 (ja) 2016-02-22 2021-09-29 ノバルティス アーゲー Fxrアゴニストを使用するための方法
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
AR108711A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
WO2018059314A1 (zh) 2016-09-28 2018-04-05 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
CN106632294A (zh) 2016-12-15 2017-05-10 宁波百纳西药业有限公司 一种螺环化合物及其药物用途

Similar Documents

Publication Publication Date Title
JP2021501220A5 (enExample)
JP3544675B2 (ja) 血管形成阻害活性を有するフタラジン
CA2807620C (en) Pharmaceutically active compounds as axl inhibitors
JP6884102B2 (ja) がんの治療のための化合物
JP2020514267A5 (enExample)
JP2006520805A5 (enExample)
HRP20160539T1 (hr) Antagonisti trpv4
TW202122387A (zh) Mta協同性之prmt5抑制劑
JP2014518214A5 (enExample)
JP2020526556A5 (enExample)
JP2016519096A5 (enExample)
JP2014528479A5 (enExample)
KR20130109210A (ko) Fxr을 조절하기 위한 조성물 및 방법
JP2016172739A5 (enExample)
RU2019118623A (ru) Пирролопиримидины в качестве потенциаторов мвтр
JP2012532931A5 (enExample)
JP2019206577A (ja) 一過性受容体電位a1イオンチャネルの阻害
JP2021501806A5 (enExample)
JP2014525444A5 (enExample)
JP2014530237A5 (enExample)
JP2010515734A5 (enExample)
JP2011519891A5 (enExample)
JP2009515814A5 (enExample)
JP2013505930A5 (enExample)
JP2016507551A5 (enExample)